

Curriculum Vitae

	Name (First Name / Middle Name / Last Name)	Remo Panaccione
	Title (Prof. Dr., etc.)	Professor of Medicine
	Affiliation	University of Calgary
	Country	CANADA
	E-mail	rpanacci@ucalgary.ca

Educational Background

MD-Western University, LONDON, ON, CANADA
 IM Residency- Western University, LONDON, ON, CANADA
 GI Residency- Western University, LONDON, ON, CANADA
 IBD Fellowship-Mayo Clinic School of Medicine, ROCHESTER, MN, USA

Professional Career

Dr. Panaccione is a distinguished Professor of Medicine and the Director of the Inflammatory Bowel Disease (IBD) Unit at the University of Calgary. He also serves as the Dean of MD Admissions and directs the university's IBD Fellowship Program. Dr. Panaccione holds the prestigious Crohn's and Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease.

A dedicated clinician, educator, and researcher, Dr. Panaccione has received numerous honors, including recognition as a Canadian Association of Gastroenterology Visiting Professor, the 2020 Crohn's and Colitis Canada Outstanding Physician of the Year, and the 2024 Research Leadership Award. From 2020 to 2024, he has also been recognized as a Clarivate Research Scholar, placing him in the top 1% of the world's most-cited researchers.

With an extensive publication record, Dr. Panaccione has co-authored over 400 peer-reviewed manuscripts, 9 book chapters, and 726 abstracts. His research has appeared in leading journals, including the *New England Journal of Medicine*, *The Lancet*, *JAMA*, *Nature*, and *Annals of Internal Medicine*. He is also an active peer reviewer for prestigious journals such as *NEJM*, *The Lancet*, *Gastroenterology*, and *Gut*. As a founding member of the Crohn's and Colitis Canada PACE initiative, a \$5 million program, Dr. Panaccione is widely regarded as an authority on IBD therapeutics and has contributed extensively to the development of national guidelines for the Canadian Association of Gastroenterology.

Research Field

Inflammatory Bowel Disease

Main Scientific Publications

1. [US and European Patient and Health Care Professional Perspectives on Fatigue in Ulcerative Colitis and Crohn's Disease: Results From the Communicating Needs and Features of Inflammatory Bowel Disease Experiences Survey.](#)
Panaccione R, Bleakman AP, Schreiber S, Travis S, Dubinsky M, Hibi T, Gobble TH, Panni T, Kayhan C, Flynn EJ, Favia AD, Atkinson C, Rubin DT.
Crohns Colitis 360. 2025 Mar 18;7(2):otaf011
2. [Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.](#)
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S.
Lancet Gastroenterol Hepatol. 2025 Jun;10(6):507-519. doi: 10.1016/S2468-1253(25)00017-2.
3. [Inflammatory Bowel Disease and Cardiovascular Disease.](#)
Panaccione R.
Gastroenterol Hepatol (N Y). 2024 Oct;20(10):634-637.
4. [What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?](#)
Panaccione R.
J Can Assoc Gastroenterol. 2025 Feb 21;8(Suppl 2):S1-S5. doi: 10.1093/jcag/gwae053. eCollection 2025 Mar.
5. [Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.](#)
Panaccione R, Ferrante M, Dotan I, Panés J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G.
Clin Gastroenterol Hepatol. 2025 Feb 3:S1542-3565(25)00082-5. doi: 10.1016/j.cgh.2024.12.023. Online ahead of print.
6. [Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.](#)
Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M.
J Crohns Colitis. 2025 Jan 11;19(1):jjaf005.
7. [Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.](#)
Panaccione R, Ma C, Jairath V, Dignass A, Joshi N, Clark R, Griffith J, Kligys K, Semwal M, Smith Z, Mitchell D, Nunag D, Ferrante M.
J Crohns Colitis. 2025 Feb 4;19(2):jjae128. doi: 10.1093/ecco-jcc/jjae128.
8. [Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.](#)
Panaccione R.
Aliment Pharmacol Ther. 2024 Feb;59(4):581-582. doi: 10.1111/apt.17853.
9. [Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.](#)
Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR, Loftus EV Jr, Chen S, Gonzalez YS, Leonard C, Hébuterne X, Lindsay JO, Cao Q, Nakase H, Colombel JF, Vermeire S.
Aliment Pharmacol Ther. 2024 Feb;59(3):393-408. doi: 10.1111/apt.17816. Epub 2023 Nov 27.
10. [Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.](#)
Panaccione R, Collins EB, Melmed GY, Vermeire S, Danese S, Higgins PDR, Kwon CS, Zhou W, Ilo D, Sharma D, Sanchez Gonzalez Y, Wang ST.
Crohns Colitis 360. 2023 Mar 1;5(2):otad009. doi: 10.1093/crocol/otad009. eCollection 2023 Apr.
11. [Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.](#)
Panaccione R, Lee WJ, Clark R, Kligys K, Campden RI, Grieve S, Raine T.
Adv Ther. 2023 May;40(5):2051-2081. doi: 10.1007/s12325-023-02457-6. Epub 2023 Mar 17.
12. [Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.](#)
Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M.
Aliment Pharmacol Ther. 2022 Jun;55(12):1534-1544. doi: 10.1111/apt.16848. Epub 2022 Mar 5.
13. [Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.](#)
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam

RP, Sands BE, Marano C.

Aliment Pharmacol Ther. 2020 Dec;52(11-12):1658-1675. doi: 10.1111/apt.16119. Epub 2020 Oct 21.

14. [Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.](#)

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

J Can Assoc Gastroenterol. 2019 Aug;2(3):e1-e34. doi: 10.1093/jcag/gwz019. Epub 2018 Jul 10.

15. [Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.](#)

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR.

Gut. 2020 Apr;69(4):658-664. doi: 10.1136/gutjnl-2019-318256. Epub 2019 Jul 8.

16. [Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.](#)

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1680-1713. doi: 10.1016/j.cgh.2019.02.043. Epub 2019 Mar 7.

17. [Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.](#)

Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF.

J Crohns Colitis. 2019 May 27;13(6):725-734. doi: 10.1093/ecco-jcc/jjy223.

18. [Briakinumab for treatment of Crohn's disease: results of a randomized trial.](#)

Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R.

Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. doi: 10.1097/MIB.0000000000000366.

19. [Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.](#)

Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P.

Gastroenterology. 2014 Feb;146(2):392-400.e3. doi: 10.1053/j.gastro.2013.10.052.

PMID: 24512909 Clinical Trial.